Sam11 personal page - To The Moon

Sam11

Sam11

No personal profile

4Follow

1Followers

0Topic

0Badge

2021-06-16

Nice read

7 Best Growth Stocks to Buy in June

2021-06-16

[Glance]

Soccer-Pogba removes Heineken bottle at Euro news conference

2021-06-16

[What]

India slams Twitter for not complying with new IT rules

2021-06-16

Good read

How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?

2021-06-16

Good read

How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?

2021-06-09

??maybe

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3578739519565731","uuid":"3578739519565731","gmtCreate":1615651542293,"gmtModify":1623899524548,"name":"Sam11","pinyin":"sam11","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":4,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":169661570,"gmtCreate":1623833334090,"gmtModify":1703820832901,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"Nice read","listText":"Nice read","text":"Nice read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169661570","repostId":"1178463933","repostType":2,"isVote":1,"tweetType":1,"viewCount":242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169660288,"gmtCreate":1623833198444,"gmtModify":1703820831415,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"[Glance]&nbsp;","listText":"[Glance]&nbsp;","text":"[Glance]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169660288","repostId":"2143767458","repostType":2,"isVote":1,"tweetType":1,"viewCount":392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169687505,"gmtCreate":1623833147907,"gmtModify":1703820827150,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"[What]&nbsp;","listText":"[What]&nbsp;","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169687505","repostId":"2143678757","repostType":2,"isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169686137,"gmtCreate":1623832930129,"gmtModify":1703820820761,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169686137","repostId":"2143530687","repostType":4,"repost":{"id":"2143530687","pubTimestamp":1623829500,"share":"https://ttm.financial/m/news/2143530687?lang=&edition=fundamental","pubTime":"2021-06-16 15:45","market":"us","language":"en","title":"How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2143530687","media":"Motley Fool","summary":"It's way too early to worry.","content":"<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX). More than 129 million Americans have received&nbsp;<b>Moderna</b>'s (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.</p> \n<p>However, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?</p> \n<h2>Behind the concerns</h2> \n<p>The CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.</p> \n<p>However, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.</p> \n<p>As of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.</p> \n<p>The potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.</p> \n<h2>Reason to worry?</h2> \n<p>The CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"</p> \n<p>The number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"</p> \n<p>It's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"</p> \n<p>Based on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.</p> \n<p>That could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.</p> \n<h2>Minimal movement</h2> \n<p>Should investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.</p> \n<p>Granted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.</p> \n<p>The emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 15:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143530687","content_text":"Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.\nHowever, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?\nBehind the concerns\nThe CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.\nHowever, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.\nAs of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.\nThe potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.\nReason to worry?\nThe CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"\nThe number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"\nIt's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"\nBased on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.\nThat could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.\nMinimal movement\nShould investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.\nGranted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.\nThe emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169686980,"gmtCreate":1623832922640,"gmtModify":1703820820437,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169686980","repostId":"2143530687","repostType":4,"repost":{"id":"2143530687","pubTimestamp":1623829500,"share":"https://ttm.financial/m/news/2143530687?lang=&edition=fundamental","pubTime":"2021-06-16 15:45","market":"us","language":"en","title":"How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2143530687","media":"Motley Fool","summary":"It's way too early to worry.","content":"<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX). More than 129 million Americans have received&nbsp;<b>Moderna</b>'s (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.</p> \n<p>However, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?</p> \n<h2>Behind the concerns</h2> \n<p>The CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.</p> \n<p>However, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.</p> \n<p>As of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.</p> \n<p>The potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.</p> \n<h2>Reason to worry?</h2> \n<p>The CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"</p> \n<p>The number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"</p> \n<p>It's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"</p> \n<p>Based on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.</p> \n<p>That could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.</p> \n<h2>Minimal movement</h2> \n<p>Should investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.</p> \n<p>Granted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.</p> \n<p>The emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 15:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143530687","content_text":"Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.\nHowever, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?\nBehind the concerns\nThe CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.\nHowever, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.\nAs of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.\nThe potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.\nReason to worry?\nThe CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"\nThe number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"\nIt's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"\nBased on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.\nThat could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.\nMinimal movement\nShould investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.\nGranted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.\nThe emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":180976693,"gmtCreate":1623173920112,"gmtModify":1704197725633,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"??maybe","listText":"??maybe","text":"??maybe","images":[{"img":"https://static.tigerbbs.com/d28e084ea1ff72b5355c98bf8c89fe09","width":"1125","height":"2499"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180976693","isVote":1,"tweetType":1,"viewCount":236,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":169661570,"gmtCreate":1623833334090,"gmtModify":1703820832901,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"Nice read","listText":"Nice read","text":"Nice read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169661570","repostId":"1178463933","repostType":2,"repost":{"id":"1178463933","pubTimestamp":1623824661,"share":"https://ttm.financial/m/news/1178463933?lang=&edition=fundamental","pubTime":"2021-06-16 14:24","market":"us","language":"en","title":"7 Best Growth Stocks to Buy in June","url":"https://stock-news.laohu8.com/highlight/detail?id=1178463933","media":"InvestorPlace","summary":"Growth stocks have taken an absolute beating. Let's look at a handful of the best to buy this month.","content":"<p>Growth stocks have taken an absolute beating. Let's look at a handful of the best to buy this month.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c7d5e291cb00ad126c12d7ed57c26719\" tg-width=\"1024\" tg-height=\"576\"><span>Source: Shutterstock</span></p>\n<p></p>\n<p>It’s no secret that growth stocks have taken an absolute beating over the last couple months. In fact, even though there’s been a decent bounce from the recent low, this group has been engulfed in a brutal bear market. As a result, it’s harder to find growth stocks to buy.</p>\n<p>That’s even as other indices have hit new all-time highs, and many are sitting just below those highs. The crosscurrents we’ve experienced in the stock market via sector and asset rotation have been pretty wild over the past few months.</p>\n<p>However, these are the types of rotations we should be<i>running toward</i>— not away from.</p>\n<p>Obviously we don’t want to be buying low-quality stocks that have been obliterated. With that being said, many high-quality names were thrown out with these losing stocks. As a result, they’ve suffered declines of 30% to 50% in the past several months.</p>\n<p>I am a&nbsp;huge advocate of scooping up growth stocks&nbsp;on these types of declines. So let’s look at seven of them now.</p>\n<ul>\n <li><b>Roku</b>(NASDAQ:<b><u>ROKU</u></b>)</li>\n <li><b>Square</b>(NYSE:<b><u>SQ</u></b>)</li>\n <li><b>Sea Ltd</b>(NYSE:<b><u>SE</u></b>)</li>\n <li><b>Twilio</b>(NYSE:<b><u>TWLO</u></b>)</li>\n <li><b>Snap</b>(NYSE:<b><u>SNAP</u></b>)</li>\n <li><b>The Trade Desk</b>(NASDAQ:<b><u>TTD</u></b>)</li>\n <li><b>Shopify</b>(NYSE:<b><u>SHOP</u></b>)</li>\n</ul>\n<p><b>Roku (ROKU)</b></p>\n<p>With its move from sub-$30 in late 2018 to its recent high of almost $500, Roku has firmly cemented itself into the next generation of growth stocks. Will it grow to be the next&nbsp;<b>Apple</b>(NASDAQ:<b><u>AAPL</u></b>)? In terms of market capitalization, probably not.</p>\n<p>However, it’s firmly entrenched in a major secular growth trend. Streaming TV is not going away. It’s too convenient for customers and offers too many options to be discarded. It’s simply the new way that we digest video and Roku’s leading the charge.</p>\n<p>Too many people keep thinking of Roku as the streaming stick you put in the TV or as the smart TV you buy from the store. That’s Roku’s hardware unit, but it’s the wrong focus. The hardware is simply the gateway to the company’s<i>platform</i>.</p>\n<p>The platform has all of the leverage. It’s what’s powering the big move in gross profit, revenue growth and usage. It’s why Roku has an enormous runway of growth both domestically and internationally. Despite years to get the story right, look at how conservative the analysts remain.</p>\n<p>Revenue of $574 million&nbsp;beat estimates by almost $83 million, nearly 17% higher than consensus estimates, and was up almost 80% year over year. A surprise profit of 54 cents per share crushed expectations by 67 cents. Revenue estimates for next quarter torched expectations as well ($615 million at the midpoint vs. expectations of $546 million).</p>\n<p><b>Square (SQ)</b></p>\n<p>What do I love about Square? It’s continued push toward new technologies and features. It’s not shy about disrupting a particular space, nor does it seem worried about angering the legacy providers in various industries.</p>\n<p>It’s quickly becoming a go-to platform — there’s that word again,<i>platform</i>— for all things money.</p>\n<p>Whether you’re a small- or medium-sized business or just a single person looking to send some money, Square has various solutions at hand. Business lending, recurring revenue via point-of-service, its Cash App, payroll services, cryptocurrency trading — you name it.</p>\n<p>It’s why so many investors continue to hold this name, believing that it has a long runway of growth as it continues to gain customers.</p>\n<p>The other thing I like about Square? How well it held up during the bear market correction. Shares fell “just” 20% from peak to trough. While shedding a fifth of its value seems rough, it’s<i>much</i>better than its peers held up. Almost all of these stocks fell 40% or more. It’s even more impressive considering that Square rallied more than 250% from the March 2020 lows and it didn’t break its March lows (again, like most of its peers did in May).</p>\n<p><b>Sea Ltd (SE)</b></p>\n<p>Another stock that had impressive relative strength was Sea Ltd. In fact, this stock had a very similar performance run as Square.</p>\n<p>Shares rallied 500% from the March 2020 low to the February high and then corrected 27%. Sea stock is now only about $5 from its all-time high. This stock is incredibly resilient. Further, it’s got the growth to back it up.</p>\n<p>Analysts expect&nbsp;85% revenue growth this year and 46% growth in 2022. On the earnings front, analysts expect a loss in each of the next two years, but Sea is forecast to shrink those losses in both years.</p>\n<p>Now it’s looking to&nbsp;expand in South America too, further helping drive its growth higher.</p>\n<p>I can’t believe how well the stock has held up after such a strong run and rapid rebound. This one has plenty of relative strength.</p>\n<p><b>Twilio (TWLO)</b></p>\n<p>One of the highest-quality companies on this list, Twilio has become a growth giant. Like Roku, it wasn’t long ago that Twilio was trading below $40. Heck, at its recent low, Twilio shares were trading below $100. At its recent high though, the stock was north of $450.</p>\n<p>Twilio has become<i>the</i>premiere platform for businesses to communicate with their customers.Everyone from ride-sharing companies to&nbsp;<b>Airbnb</b>(NASDAQ:<b><u>ABNB</u></b>) to&nbsp;<b>Twitter</b>(NYSE:<b><u>TWTR</u></b>) use Twilio to communicate with customers and users, with plenty of others in between.</p>\n<p>In the world of growth, we have speculative growth stocks and established growth stocks. While it’s rewarding to catching the speculative winners that turn into the future growth giants, Twilio is an established growth giant.</p>\n<p>Its acquisition of SendGrid took Twilio to the next level by incorporating email into the communication strategy. The company is leveraging the internet and mobile devices for communication, and unless we stop traveling, buying, tweeting and other things, Twilio will be here for years and years to come.</p>\n<p><b>Snap (SNAP)</b></p>\n<p>Snap is one of Wall Street’s favorite social media giants.<b>Facebook</b>(NASDAQ:<b><u>FB</u></b>) has garnered some nice momentum lately, but Snap is absolutely one that investors will come back to and bid higher if growth stocks fetch a bid.</p>\n<p>While it took a few years for this young company to find its way, management has done so in an impressive manner. Consensus estimates now call for 55% revenue growth this year, near-50% growth in 2022 and more than 40% growth in 2023.</p>\n<p>If those estimates pan out, it will take Snap from $2.5 billion in sales in 2020 to more than $8 billion in revenue in 2024. Whoa! Now you can see where the bullish case comes from with this one.</p>\n<p>Making things even better, the company is forecast to become profitable this year, then more than triple its earnings in 2022.</p>\n<p>We’ll see how accurate some of these estimates are. But one thing seems certain and that’s that Snapchat isn’t going anywhere and it should be a significant driver of growth for the next several years.</p>\n<p>Like Square, Snap didn’t break down to new lows this quarter and fell “just” 28% from the high. Let’s see how long it takes to erase the current 10% dip from the highs.</p>\n<p><b>The Trade Desk (TTD)</b></p>\n<p>Now this one is truly perplexing. The Trade Desk became a Wall Street favorite, surging from about $150 in March 2020 to almost $1,000 by December.</p>\n<p>After a move like that, I don’t care how great the company is — the stock deserves to correct. Of course, The Trade Desk was also trading at more than 40 times revenue, which made it susceptible to the “snowball selloff” or a decline that gains serious momentum on the way down once investors discover a reason to sell it.</p>\n<p>Despite the bumpy price action, including a 50% correction off the highs, this stock looks like a bargain on the dip. Why? Because it’s a fantastic business!</p>\n<p>Co-founder and CEO Jeff Green has built a remarkable business, one that is thriving around the world — including China. That’s a big difference vs. some of the ad giants of the world, like&nbsp;<b>Alphabet</b>(NASDAQ:<b><u>GOOGL</u></b>, NASDAQ:<b><u>GOOG</u></b>) and Facebook, which aren’t allowed to operate in China.</p>\n<p>The company&nbsp;uses data to spread contracted products to reach as many potential customers as possible. As online advertising continues to grow and as advertising on streaming TV grows, so too should The Trade Desk.</p>\n<p>Perhaps one of my favorite things about this company? The cash flow and the bottom line. Despite being a growth company, this company still generates solid earnings. I expect The Trade Desk to&nbsp;generate 30%-plus revenue growth&nbsp;in each of the next three years, minimum.</p>\n<p><b>Shopify (SHOP)</b></p>\n<p>Shopify isn’t exactly flying under the radar these days. The company commands a market cap of $163 billion, making it a large cap tech stock.</p>\n<p>I wrote about this one in Dec. 2019, back when it had a $30 billion to $40 billion market cap. My case was based on the idea of the&nbsp;stock tripling in the next five to 10 years. I was certainly bullish on this stock, but clearly not bullish enough.</p>\n<p>Put simply, Shopify is revolutionizing and completely disrupting the e-commerce space. Yeah, there’s&nbsp;<b>Amazon</b>(NASDAQ:<b><u>AMZN</u></b>), but there’s enough room for two of these beasts.</p>\n<p>Shopify will have its share of ups and downs, but it’s not going anywhere soon. It’s built a can’t-live-without platform for its customers and it’s not even close to being done yet. The valuation is high, but the growth seems endless.</p>\n<p>Like others on this list, Shopify held up pretty well during the selloff. I wouldn’t hesitate to hold this name long term and take advantage of the dips.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Best Growth Stocks to Buy in June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Best Growth Stocks to Buy in June\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 14:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/7-best-growth-stocks-to-buy-in-june/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks have taken an absolute beating. Let's look at a handful of the best to buy this month.\nSource: Shutterstock\n\nIt’s no secret that growth stocks have taken an absolute beating over the ...</p>\n\n<a href=\"https://investorplace.com/2021/06/7-best-growth-stocks-to-buy-in-june/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TTD":"Trade Desk Inc.","SHOP":"Shopify Inc","SE":"Sea Ltd","TWLO":"Twilio Inc","SQ":"Block","SNAP":"Snap Inc","ROKU":"Roku Inc"},"source_url":"https://investorplace.com/2021/06/7-best-growth-stocks-to-buy-in-june/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178463933","content_text":"Growth stocks have taken an absolute beating. Let's look at a handful of the best to buy this month.\nSource: Shutterstock\n\nIt’s no secret that growth stocks have taken an absolute beating over the last couple months. In fact, even though there’s been a decent bounce from the recent low, this group has been engulfed in a brutal bear market. As a result, it’s harder to find growth stocks to buy.\nThat’s even as other indices have hit new all-time highs, and many are sitting just below those highs. The crosscurrents we’ve experienced in the stock market via sector and asset rotation have been pretty wild over the past few months.\nHowever, these are the types of rotations we should berunning toward— not away from.\nObviously we don’t want to be buying low-quality stocks that have been obliterated. With that being said, many high-quality names were thrown out with these losing stocks. As a result, they’ve suffered declines of 30% to 50% in the past several months.\nI am a huge advocate of scooping up growth stocks on these types of declines. So let’s look at seven of them now.\n\nRoku(NASDAQ:ROKU)\nSquare(NYSE:SQ)\nSea Ltd(NYSE:SE)\nTwilio(NYSE:TWLO)\nSnap(NYSE:SNAP)\nThe Trade Desk(NASDAQ:TTD)\nShopify(NYSE:SHOP)\n\nRoku (ROKU)\nWith its move from sub-$30 in late 2018 to its recent high of almost $500, Roku has firmly cemented itself into the next generation of growth stocks. Will it grow to be the next Apple(NASDAQ:AAPL)? In terms of market capitalization, probably not.\nHowever, it’s firmly entrenched in a major secular growth trend. Streaming TV is not going away. It’s too convenient for customers and offers too many options to be discarded. It’s simply the new way that we digest video and Roku’s leading the charge.\nToo many people keep thinking of Roku as the streaming stick you put in the TV or as the smart TV you buy from the store. That’s Roku’s hardware unit, but it’s the wrong focus. The hardware is simply the gateway to the company’splatform.\nThe platform has all of the leverage. It’s what’s powering the big move in gross profit, revenue growth and usage. It’s why Roku has an enormous runway of growth both domestically and internationally. Despite years to get the story right, look at how conservative the analysts remain.\nRevenue of $574 million beat estimates by almost $83 million, nearly 17% higher than consensus estimates, and was up almost 80% year over year. A surprise profit of 54 cents per share crushed expectations by 67 cents. Revenue estimates for next quarter torched expectations as well ($615 million at the midpoint vs. expectations of $546 million).\nSquare (SQ)\nWhat do I love about Square? It’s continued push toward new technologies and features. It’s not shy about disrupting a particular space, nor does it seem worried about angering the legacy providers in various industries.\nIt’s quickly becoming a go-to platform — there’s that word again,platform— for all things money.\nWhether you’re a small- or medium-sized business or just a single person looking to send some money, Square has various solutions at hand. Business lending, recurring revenue via point-of-service, its Cash App, payroll services, cryptocurrency trading — you name it.\nIt’s why so many investors continue to hold this name, believing that it has a long runway of growth as it continues to gain customers.\nThe other thing I like about Square? How well it held up during the bear market correction. Shares fell “just” 20% from peak to trough. While shedding a fifth of its value seems rough, it’smuchbetter than its peers held up. Almost all of these stocks fell 40% or more. It’s even more impressive considering that Square rallied more than 250% from the March 2020 lows and it didn’t break its March lows (again, like most of its peers did in May).\nSea Ltd (SE)\nAnother stock that had impressive relative strength was Sea Ltd. In fact, this stock had a very similar performance run as Square.\nShares rallied 500% from the March 2020 low to the February high and then corrected 27%. Sea stock is now only about $5 from its all-time high. This stock is incredibly resilient. Further, it’s got the growth to back it up.\nAnalysts expect 85% revenue growth this year and 46% growth in 2022. On the earnings front, analysts expect a loss in each of the next two years, but Sea is forecast to shrink those losses in both years.\nNow it’s looking to expand in South America too, further helping drive its growth higher.\nI can’t believe how well the stock has held up after such a strong run and rapid rebound. This one has plenty of relative strength.\nTwilio (TWLO)\nOne of the highest-quality companies on this list, Twilio has become a growth giant. Like Roku, it wasn’t long ago that Twilio was trading below $40. Heck, at its recent low, Twilio shares were trading below $100. At its recent high though, the stock was north of $450.\nTwilio has becomethepremiere platform for businesses to communicate with their customers.Everyone from ride-sharing companies to Airbnb(NASDAQ:ABNB) to Twitter(NYSE:TWTR) use Twilio to communicate with customers and users, with plenty of others in between.\nIn the world of growth, we have speculative growth stocks and established growth stocks. While it’s rewarding to catching the speculative winners that turn into the future growth giants, Twilio is an established growth giant.\nIts acquisition of SendGrid took Twilio to the next level by incorporating email into the communication strategy. The company is leveraging the internet and mobile devices for communication, and unless we stop traveling, buying, tweeting and other things, Twilio will be here for years and years to come.\nSnap (SNAP)\nSnap is one of Wall Street’s favorite social media giants.Facebook(NASDAQ:FB) has garnered some nice momentum lately, but Snap is absolutely one that investors will come back to and bid higher if growth stocks fetch a bid.\nWhile it took a few years for this young company to find its way, management has done so in an impressive manner. Consensus estimates now call for 55% revenue growth this year, near-50% growth in 2022 and more than 40% growth in 2023.\nIf those estimates pan out, it will take Snap from $2.5 billion in sales in 2020 to more than $8 billion in revenue in 2024. Whoa! Now you can see where the bullish case comes from with this one.\nMaking things even better, the company is forecast to become profitable this year, then more than triple its earnings in 2022.\nWe’ll see how accurate some of these estimates are. But one thing seems certain and that’s that Snapchat isn’t going anywhere and it should be a significant driver of growth for the next several years.\nLike Square, Snap didn’t break down to new lows this quarter and fell “just” 28% from the high. Let’s see how long it takes to erase the current 10% dip from the highs.\nThe Trade Desk (TTD)\nNow this one is truly perplexing. The Trade Desk became a Wall Street favorite, surging from about $150 in March 2020 to almost $1,000 by December.\nAfter a move like that, I don’t care how great the company is — the stock deserves to correct. Of course, The Trade Desk was also trading at more than 40 times revenue, which made it susceptible to the “snowball selloff” or a decline that gains serious momentum on the way down once investors discover a reason to sell it.\nDespite the bumpy price action, including a 50% correction off the highs, this stock looks like a bargain on the dip. Why? Because it’s a fantastic business!\nCo-founder and CEO Jeff Green has built a remarkable business, one that is thriving around the world — including China. That’s a big difference vs. some of the ad giants of the world, like Alphabet(NASDAQ:GOOGL, NASDAQ:GOOG) and Facebook, which aren’t allowed to operate in China.\nThe company uses data to spread contracted products to reach as many potential customers as possible. As online advertising continues to grow and as advertising on streaming TV grows, so too should The Trade Desk.\nPerhaps one of my favorite things about this company? The cash flow and the bottom line. Despite being a growth company, this company still generates solid earnings. I expect The Trade Desk to generate 30%-plus revenue growth in each of the next three years, minimum.\nShopify (SHOP)\nShopify isn’t exactly flying under the radar these days. The company commands a market cap of $163 billion, making it a large cap tech stock.\nI wrote about this one in Dec. 2019, back when it had a $30 billion to $40 billion market cap. My case was based on the idea of the stock tripling in the next five to 10 years. I was certainly bullish on this stock, but clearly not bullish enough.\nPut simply, Shopify is revolutionizing and completely disrupting the e-commerce space. Yeah, there’s Amazon(NASDAQ:AMZN), but there’s enough room for two of these beasts.\nShopify will have its share of ups and downs, but it’s not going anywhere soon. It’s built a can’t-live-without platform for its customers and it’s not even close to being done yet. The valuation is high, but the growth seems endless.\nLike others on this list, Shopify held up pretty well during the selloff. I wouldn’t hesitate to hold this name long term and take advantage of the dips.","news_type":1},"isVote":1,"tweetType":1,"viewCount":242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169660288,"gmtCreate":1623833198444,"gmtModify":1703820831415,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"[Glance]&nbsp;","listText":"[Glance]&nbsp;","text":"[Glance]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169660288","repostId":"2143767458","repostType":2,"repost":{"id":"2143767458","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623829458,"share":"https://ttm.financial/m/news/2143767458?lang=&edition=fundamental","pubTime":"2021-06-16 15:44","market":"us","language":"en","title":"Soccer-Pogba removes Heineken bottle at Euro news conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2143767458","media":"Reuters","summary":"June 16 (Reuters) - France midfielder Paul Pogba removed a bottle of Heineken beer that had been pla","content":"<html><body><p>June 16 (Reuters) - France midfielder Paul Pogba removed a bottle of Heineken beer that had been placed in front of him at a Euro 2020 news conference on Tuesday, a day after Portugal captain Cristiano Ronaldo moved aside Coca-Cola bottles in a similar set-up. </p><p>   Pogba, a practising Muslim, removed the bottle when he sat down to speak to the media after he was named 'Man of the Match' in France's 1-0 Group F win over Germany.</p><p>   Reuters has request comment from Heineken, who are <a href=\"https://laohu8.com/S/AONE\">one</a> of the official sponsors of Euro 2020.</p><p>   On Monday, Ronaldo removed two bottles of Coca-Cola at a news conference and held up a bottle of water shouting \"Agua\" in Portuguese.  </p><p> (Reporting by Manasi Pathak in Bengaluru; Editing by Peter Rutherford )</p><p>((Manasi.Pathak@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soccer-Pogba removes Heineken bottle at Euro news conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoccer-Pogba removes Heineken bottle at Euro news conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-16 15:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>June 16 (Reuters) - France midfielder Paul Pogba removed a bottle of Heineken beer that had been placed in front of him at a Euro 2020 news conference on Tuesday, a day after Portugal captain Cristiano Ronaldo moved aside Coca-Cola bottles in a similar set-up. </p><p>   Pogba, a practising Muslim, removed the bottle when he sat down to speak to the media after he was named 'Man of the Match' in France's 1-0 Group F win over Germany.</p><p>   Reuters has request comment from Heineken, who are <a href=\"https://laohu8.com/S/AONE\">one</a> of the official sponsors of Euro 2020.</p><p>   On Monday, Ronaldo removed two bottles of Coca-Cola at a news conference and held up a bottle of water shouting \"Agua\" in Portuguese.  </p><p> (Reporting by Manasi Pathak in Bengaluru; Editing by Peter Rutherford )</p><p>((Manasi.Pathak@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KO":"可口可乐"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143767458","content_text":"June 16 (Reuters) - France midfielder Paul Pogba removed a bottle of Heineken beer that had been placed in front of him at a Euro 2020 news conference on Tuesday, a day after Portugal captain Cristiano Ronaldo moved aside Coca-Cola bottles in a similar set-up.    Pogba, a practising Muslim, removed the bottle when he sat down to speak to the media after he was named 'Man of the Match' in France's 1-0 Group F win over Germany.   Reuters has request comment from Heineken, who are one of the official sponsors of Euro 2020.   On Monday, Ronaldo removed two bottles of Coca-Cola at a news conference and held up a bottle of water shouting \"Agua\" in Portuguese.   (Reporting by Manasi Pathak in Bengaluru; Editing by Peter Rutherford )((Manasi.Pathak@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169687505,"gmtCreate":1623833147907,"gmtModify":1703820827150,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"[What]&nbsp;","listText":"[What]&nbsp;","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169687505","repostId":"2143678757","repostType":2,"repost":{"id":"2143678757","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623827561,"share":"https://ttm.financial/m/news/2143678757?lang=&edition=fundamental","pubTime":"2021-06-16 15:12","market":"us","language":"en","title":"India slams Twitter for not complying with new IT rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2143678757","media":"Reuters","summary":"By Sankalp Phartiyal   NEW DELHI, June 16 (Reuters) - India's technology minister said on Tuesday th","content":"<html><body><p>By Sankalp Phartiyal</p><p>   NEW DELHI, June 16 (Reuters) - India's technology minister said on Tuesday that <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> Inc    had deliberately defied and failed to comply with the country's new IT rules, which became effective in late May.</p><p>   The new rules or the so-called Intermediary Guidelines, announced in February, are aimed at regulating content on social media firms such as <a href=\"https://laohu8.com/S/FB\">Facebook</a>   , its WhatsApp messenger and Twitter, making them more accountable to legal requests for swift removal of posts and sharing details on the originators of messages.  </p><p>   The rules also require big social media companies to set up grievance redressal mechanisms and appoint new executives to coordinate with law enforcement.</p><p>   India's technology ministry wrote to Twitter on June 5, warning the company of \"unintended consequences\" if it did not obey the rules, Reuters previously reported.  </p><p>   Prasad did not directly say on Tuesday whether Twitter had lost intermediary protections, but a senior government official told Reuters that Twitter may no longer be eligible to seek liability exemptions as an intermediary or the host of user content in India due to its failure to comply with new IT rules.</p><p>   \"There are numerous queries arising as to whether Twitter is entitled to safe harbour provision,\" Prasad tweeted. \"However, the simple fact of the matter is that Twitter has failed to comply with the Intermediary Guidelines that came into effect from the 26th of May.\"</p><p>   Twitter, Prasad added, had chosen the \"path of deliberate defiance when it comes to the Intermediary Guidelines.\"</p><p>   Twitter did not respond to a request for comment though it said on Monday it was keeping India's technology ministry apprised of the steps it was taking. </p><p>   \"An interim Chief Compliance Officer has been retained and details will be shared with the Ministry directly soon,\" it said. \"Twitter continues to make every effort to comply with the new guidelines.</p><p>   New Delhi-based digital advocacy group Internet Freedom Foundation said it was only up to courts, and not the government, to decide whether companies such as Twitter remained intermediaries for alleged non-compliance such as appointment of executives.</p><p>   Growing tensions between India's government and U.S. big tech have riled firms that have spent millions of dollars to build hubs in their largest growth market, to the extent some are rethinking expansion plans, people close to the matter have told Reuters previously.  </p><p> (Reporting by Sankalp Phartiyal; Editing by Raju Gopalakrishnan)</p><p>((sankalp.phartiyal@thomsonreuters.com; +91-11-49548064;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India slams Twitter for not complying with new IT rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia slams Twitter for not complying with new IT rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-16 15:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>By Sankalp Phartiyal</p><p>   NEW DELHI, June 16 (Reuters) - India's technology minister said on Tuesday that <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> Inc    had deliberately defied and failed to comply with the country's new IT rules, which became effective in late May.</p><p>   The new rules or the so-called Intermediary Guidelines, announced in February, are aimed at regulating content on social media firms such as <a href=\"https://laohu8.com/S/FB\">Facebook</a>   , its WhatsApp messenger and Twitter, making them more accountable to legal requests for swift removal of posts and sharing details on the originators of messages.  </p><p>   The rules also require big social media companies to set up grievance redressal mechanisms and appoint new executives to coordinate with law enforcement.</p><p>   India's technology ministry wrote to Twitter on June 5, warning the company of \"unintended consequences\" if it did not obey the rules, Reuters previously reported.  </p><p>   Prasad did not directly say on Tuesday whether Twitter had lost intermediary protections, but a senior government official told Reuters that Twitter may no longer be eligible to seek liability exemptions as an intermediary or the host of user content in India due to its failure to comply with new IT rules.</p><p>   \"There are numerous queries arising as to whether Twitter is entitled to safe harbour provision,\" Prasad tweeted. \"However, the simple fact of the matter is that Twitter has failed to comply with the Intermediary Guidelines that came into effect from the 26th of May.\"</p><p>   Twitter, Prasad added, had chosen the \"path of deliberate defiance when it comes to the Intermediary Guidelines.\"</p><p>   Twitter did not respond to a request for comment though it said on Monday it was keeping India's technology ministry apprised of the steps it was taking. </p><p>   \"An interim Chief Compliance Officer has been retained and details will be shared with the Ministry directly soon,\" it said. \"Twitter continues to make every effort to comply with the new guidelines.</p><p>   New Delhi-based digital advocacy group Internet Freedom Foundation said it was only up to courts, and not the government, to decide whether companies such as Twitter remained intermediaries for alleged non-compliance such as appointment of executives.</p><p>   Growing tensions between India's government and U.S. big tech have riled firms that have spent millions of dollars to build hubs in their largest growth market, to the extent some are rethinking expansion plans, people close to the matter have told Reuters previously.  </p><p> (Reporting by Sankalp Phartiyal; Editing by Raju Gopalakrishnan)</p><p>((sankalp.phartiyal@thomsonreuters.com; +91-11-49548064;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","QNETCN":"纳斯达克中美互联网老虎指数","09086":"华夏纳指-U","TWTR":"Twitter"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143678757","content_text":"By Sankalp Phartiyal   NEW DELHI, June 16 (Reuters) - India's technology minister said on Tuesday that Twitter Inc    had deliberately defied and failed to comply with the country's new IT rules, which became effective in late May.   The new rules or the so-called Intermediary Guidelines, announced in February, are aimed at regulating content on social media firms such as Facebook   , its WhatsApp messenger and Twitter, making them more accountable to legal requests for swift removal of posts and sharing details on the originators of messages.     The rules also require big social media companies to set up grievance redressal mechanisms and appoint new executives to coordinate with law enforcement.   India's technology ministry wrote to Twitter on June 5, warning the company of \"unintended consequences\" if it did not obey the rules, Reuters previously reported.     Prasad did not directly say on Tuesday whether Twitter had lost intermediary protections, but a senior government official told Reuters that Twitter may no longer be eligible to seek liability exemptions as an intermediary or the host of user content in India due to its failure to comply with new IT rules.   \"There are numerous queries arising as to whether Twitter is entitled to safe harbour provision,\" Prasad tweeted. \"However, the simple fact of the matter is that Twitter has failed to comply with the Intermediary Guidelines that came into effect from the 26th of May.\"   Twitter, Prasad added, had chosen the \"path of deliberate defiance when it comes to the Intermediary Guidelines.\"   Twitter did not respond to a request for comment though it said on Monday it was keeping India's technology ministry apprised of the steps it was taking.    \"An interim Chief Compliance Officer has been retained and details will be shared with the Ministry directly soon,\" it said. \"Twitter continues to make every effort to comply with the new guidelines.   New Delhi-based digital advocacy group Internet Freedom Foundation said it was only up to courts, and not the government, to decide whether companies such as Twitter remained intermediaries for alleged non-compliance such as appointment of executives.   Growing tensions between India's government and U.S. big tech have riled firms that have spent millions of dollars to build hubs in their largest growth market, to the extent some are rethinking expansion plans, people close to the matter have told Reuters previously.   (Reporting by Sankalp Phartiyal; Editing by Raju Gopalakrishnan)((sankalp.phartiyal@thomsonreuters.com; +91-11-49548064;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169686980,"gmtCreate":1623832922640,"gmtModify":1703820820437,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169686980","repostId":"2143530687","repostType":4,"repost":{"id":"2143530687","pubTimestamp":1623829500,"share":"https://ttm.financial/m/news/2143530687?lang=&edition=fundamental","pubTime":"2021-06-16 15:45","market":"us","language":"en","title":"How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2143530687","media":"Motley Fool","summary":"It's way too early to worry.","content":"<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX). More than 129 million Americans have received&nbsp;<b>Moderna</b>'s (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.</p> \n<p>However, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?</p> \n<h2>Behind the concerns</h2> \n<p>The CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.</p> \n<p>However, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.</p> \n<p>As of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.</p> \n<p>The potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.</p> \n<h2>Reason to worry?</h2> \n<p>The CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"</p> \n<p>The number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"</p> \n<p>It's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"</p> \n<p>Based on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.</p> \n<p>That could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.</p> \n<h2>Minimal movement</h2> \n<p>Should investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.</p> \n<p>Granted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.</p> \n<p>The emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 15:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143530687","content_text":"Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.\nHowever, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?\nBehind the concerns\nThe CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.\nHowever, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.\nAs of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.\nThe potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.\nReason to worry?\nThe CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"\nThe number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"\nIt's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"\nBased on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.\nThat could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.\nMinimal movement\nShould investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.\nGranted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.\nThe emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169686137,"gmtCreate":1623832930129,"gmtModify":1703820820761,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169686137","repostId":"2143530687","repostType":4,"repost":{"id":"2143530687","pubTimestamp":1623829500,"share":"https://ttm.financial/m/news/2143530687?lang=&edition=fundamental","pubTime":"2021-06-16 15:45","market":"us","language":"en","title":"How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2143530687","media":"Motley Fool","summary":"It's way too early to worry.","content":"<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX). More than 129 million Americans have received&nbsp;<b>Moderna</b>'s (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.</p> \n<p>However, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?</p> \n<h2>Behind the concerns</h2> \n<p>The CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.</p> \n<p>However, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.</p> \n<p>As of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.</p> \n<p>The potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.</p> \n<h2>Reason to worry?</h2> \n<p>The CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"</p> \n<p>The number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"</p> \n<p>It's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"</p> \n<p>Based on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.</p> \n<p>That could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.</p> \n<h2>Minimal movement</h2> \n<p>Should investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.</p> \n<p>Granted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.</p> \n<p>The emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 15:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143530687","content_text":"Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.\nHowever, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?\nBehind the concerns\nThe CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.\nHowever, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.\nAs of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.\nThe potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.\nReason to worry?\nThe CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"\nThe number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"\nIt's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"\nBased on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.\nThat could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.\nMinimal movement\nShould investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.\nGranted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.\nThe emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":180976693,"gmtCreate":1623173920112,"gmtModify":1704197725633,"author":{"id":"3578739519565731","authorId":"3578739519565731","name":"Sam11","avatar":"https://static.tigerbbs.com/d7477554f57017596db2ebd94cbf4004","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578739519565731","authorIdStr":"3578739519565731"},"themes":[],"htmlText":"??maybe","listText":"??maybe","text":"??maybe","images":[{"img":"https://static.tigerbbs.com/d28e084ea1ff72b5355c98bf8c89fe09","width":"1125","height":"2499"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180976693","isVote":1,"tweetType":1,"viewCount":236,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}